Oppenheimer reiterated coverage on Arvinas with a new price target

2/28/24 8:22:45 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Oppenheimer reiterated coverage of Arvinas with a rating of Outperform and set a new price target of $80.00 from $95.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ARVN

Date	Price Target	Rating	Analyst
6/2/2025	$9.00	Outperform → Market Perform	Leerink Partners
5/5/2025	$11.00	Buy → Hold	Truist
5/2/2025	$10.00	Buy → Hold	Jefferies
5/2/2025		Buy → Hold	TD Cowen
3/13/2025	$70.00 → $15.00	Buy → Neutral	Goldman
3/12/2025	$57.00 → $12.00	Outperform → Neutral	Wedbush
3/11/2025		Outperform → Perform	Oppenheimer
12/10/2024	$69.00	Buy	BTIG Research